全文获取类型
收费全文 | 189篇 |
免费 | 12篇 |
国内免费 | 1篇 |
专业分类
儿科学 | 6篇 |
妇产科学 | 5篇 |
基础医学 | 23篇 |
口腔科学 | 2篇 |
临床医学 | 24篇 |
内科学 | 49篇 |
皮肤病学 | 2篇 |
神经病学 | 5篇 |
特种医学 | 3篇 |
外科学 | 15篇 |
预防医学 | 26篇 |
药学 | 8篇 |
肿瘤学 | 34篇 |
出版年
2023年 | 2篇 |
2022年 | 2篇 |
2021年 | 7篇 |
2019年 | 11篇 |
2018年 | 9篇 |
2017年 | 5篇 |
2016年 | 3篇 |
2015年 | 8篇 |
2014年 | 7篇 |
2013年 | 14篇 |
2012年 | 17篇 |
2011年 | 23篇 |
2010年 | 12篇 |
2009年 | 10篇 |
2008年 | 20篇 |
2007年 | 16篇 |
2006年 | 11篇 |
2005年 | 4篇 |
2004年 | 8篇 |
2003年 | 1篇 |
2002年 | 4篇 |
2001年 | 1篇 |
2000年 | 3篇 |
1995年 | 1篇 |
1994年 | 1篇 |
1993年 | 1篇 |
1988年 | 1篇 |
排序方式: 共有202条查询结果,搜索用时 15 毫秒
11.
12.
Bathen TF Jensen LR Sitter B Fjösne HE Halgunset J Axelson DE Gribbestad IS Lundgren S 《Breast cancer research and treatment》2007,106(2):181-189
The purpose of the study was to evaluate the use of metabolic phenotype, described by high-resolution magic angle spinning
magnetic resonance spectroscopy (HR MAS MRS), as a tool for prediction of histological grade, hormone status, and axillary
lymphatic spread in breast cancer patients. Biopsies from breast cancer (n = 91) and adjacent non-involved tissue (n = 48) were excised from patients (n = 77) during surgery. HR MAS MR spectra of intact samples were acquired. Multivariate models relating spectral data to histological
grade, lymphatic spread, and hormone status were designed. The multivariate methods applied were variable reduction by principal
component analysis (PCA) or partial least-squares regression-uninformative variable elimination (PLS-UVE), and modelling by
PLS, probabilistic neural network (PNN), or cascade correlation neural network. In the end, model verification by prediction
of blind samples (n = 12) was performed. Validation of PNN training resulted in sensitivity and specificity ranging from 83 to 100% for all predictions.
Verification of models by blind sample testing showed that hormone status was well predicted by both PNN and PLS (11 of 12
correct), lymphatic spread was best predicted by PLS (8 of 12), whereas PLS-UVE PNN was the best approach for predicting grade
(9 of 12 correct). MR-determined metabolic phenotype may have a future role as a supplement for clinical decision-making-concerning
adjuvant treatment and the adaptation to more individualised treatment protocols. 相似文献
13.
Kristell Rioual Edurne Unanua Soizic Laguitton Mireille Garreau Dominique Boulmier Pascal Haigron Christophe Leclercq Jean-Louis Coatrieux 《Computerized medical imaging and graphics》2005,29(6):431-439
The objective of this paper is twofold: (i) to show how multislice computed tomography (MSCT) data sets bring the information required for cardiac resynchronisation therapy (CRT) planning; (ii) to demonstrate the feasibility of 3D navigation into the veins where left ventricular leads have to be placed. The former has been achieved by exploring and labelling the cardiac structures of concern, the latter has been performed by using the concept of virtual navigation with high resolution surface detection and estimation algorithms. 相似文献
14.
Mazo M Cemborain A Gavira JJ Abizanda G Araña M Casado M Soriano M Hernández S Moreno C Ecay M Albiasu E Belzunce M Orbe J Páramo JA Merino J Peñuelas I Verdugo JM Pelacho B Prosper F 《Cell transplantation》2012,21(5):1023-1037
Fresh adipose-derived cells have been shown to be effective in the treatment of acute myocardial infarction (MI), but their role in the chronic setting is unknown. We sought to determine the long-term effect of the adipose derived-stromal vascular fraction (SVF) cell transplantation in a rat model of chronic MI. MI was induced in 82 rats by permanent coronary artery ligation and 5 weeks later rats were allocated to receive an intramyocardial injection of 10(7) GFP-expressing fresh SVF cells or culture media as control. Heart function and tissue metabolism were determined by echocardiography and (18)F-FDG-microPET, respectively, and histological studies were performed for up to 3 months after transplantation. SVF induced a statistically significant long-lasting (3 months) improvement in cardiac function and tissue metabolism that was associated with increased revascularization and positive heart remodeling, with a significantly smaller infarct size, thicker infarct wall, lower scar fibrosis, and lower cardiac hypertrophy. Importantly, injected cells engrafted and were detected in the treated hearts for at least 3 months, directly contributing to the vasculature and myofibroblasts and at negligible levels to cardiomyocytes. Furthermore, SVF release of angiogenic (VEGF and HGF) and proinflammatory (MCP-1) cytokines, as well as TIMP1 and TIMP4, was demonstrated in vitro and in vivo, strongly suggesting that they have a trophic effect. These results show the potential of SVF to contribute to the regeneration of ischemic tissue and to provide a long-term functional benefit in a rat model of chronic MI, by both direct and indirect mechanisms. 相似文献
15.
16.
17.
18.
Arriola E Moreno A Varela M Serra JM Falo C Benito E Escobedo AP 《European journal of cancer (Oxford, England : 1990)》2006,42(17):2954-2960
AimTo study the predictive role of HER-2 and Topoisomerase IIα (TOP2A) in response to primary doxorubicin.MethodsTwo hundred and thirty-two patients with operable breast cancer were treated with doxorubicin prior to surgery. ER, PgR, grade, Ki-67 and HER-2 status were prospectively assessed. HER-2 overexpression was evaluated with immunohistochemistry; positive cases were then studied for gene copy number of HER-2, TOP2A and chromosome 17 centromere by chromogenic in situ hybridisation. Clinical response was assessed by mammography. Pathological response was evaluated as the percentage of tumour replaced by changes due to chemotherapy.ResultsHER-2 amplification was associated with clinical response (p = 0.04). ER and PgR negativity, high Ki-67 and HER-2 amplification significantly correlated to pathological response (p < 0.05). Tumours with coamplification of HER-2 and TOP2A showed a higher percentage of pathological changes (p = 0.6). However, in the multivariate analysis for complete pathological response, ER negativity and high Ki-67 index were the only parameters that maintained statistical significance.ConclusionHER2 and Topoisomerase IIα amplification failed to show an association with pathological response to doxorubicin, whereas ER negativity and a high proliferation rate were predictive of complete pathological response to this regime. 相似文献
19.
20.
Gomez R Gonzalez-Izquierdo M Zimmermann RC Novella-Maestre E Alonso-Muriel I Sanchez-Criado J Remohi J Simon C Pellicer A 《Endocrinology》2006,147(11):5400-5411
No specific treatment is available for ovarian hyperstimulation syndrome (OHSS), the most important complication in infertile women treated with gonadotropins. OHSS is caused by increased vascular permeability (VP) through ovarian hypersecretion of vascular endothelial growth factor (VEGF)-activating VEGF receptor 2 (VEGFR-2). We previously demonstrated in an OHSS rodent model that increased VP was prevented by inactivating VEGFR-2 with a receptor antagonist (SU5416). However, due to its toxicity (thromboembolism) and disruption of VEGFR-2-dependent angiogenic processes critical for pregnancy, this kind of compound cannot be used clinically to prevent OHSS. Dopamine receptor 2 (Dp-r2) agonists, used in the treatment of human hyperprolactinemia including pregnancy, inhibit VEGFR-2-dependent VP and angiogenesis when administered at high doses in animal cancer models. To test whether VEGFR-2-dependent VP and angiogenesis could be segregated in a dose-dependent fashion with the Dp-r2 agonist cabergoline, a well-established OHSS rat model supplemented with prolactin was used. A 100 microg/kg low-dose Dp-r2 agonist cabergoline reversed VEGFR-2-dependent VP without affecting luteal angiogenesis through partial inhibition of ovarian VEGFR-2 phosphorylation levels. No luteolytic effects (serum progesterone levels and luteal apoptosis unaffected) were observed. Cabergoline administration also did not affect VEGF/VEGFR-2 ovarian mRNA levels. Results in the animal model and the safe clinical profile of Dp-r2 agonists encouraged us to administer cabergoline to oocyte donors at high risk for developing the syndrome. Prophylactic administration of cabergoline (5-10 microg/kg x d) decreased the occurrence of OHSS from 65% (controls) to 25% (treatment). Therefore, a specific, safe treatment for OHSS is now available. 相似文献